Attorney Docket No. 25619-501 (Formerly)

Date of Deposit: April 25, 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Express Mail Label No.: EV 139506881 US

SERIAL NUMBER:

09/806,400

EXAMINER:

R. Schwadron

FILING DATE:

March 30, 2001

Schoenfeld et al.

ART UNIT:

1644

For:

COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS

Assistant Commissioner for Patents Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-identified application:

- 1. Response to Restriction Requirement and Preliminary Amendment (5 pgs.); and,
- 2. Return Postcard.

The Commissioner is hereby authorized to charge payment of any filing fees required in connection with the papers transmitted herewith, or credit any overpayment of same, to Deposit Account No. 50-0311 Reference No. 25619-501. A duplicate copy of this transmittal letter is transmitted herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529

Barry J. Marenberg, Reg. No. 40,715

Attorneys for Applicants c/o MINTZ LEVIN

One Financial Center

Boston, Massachusetts 02111

Tel.: (617) 542-6000

Fax: (617) 542-2241

Dated: April 25, 2003

Express Mail Label No.: EV 139506881 US

Parte of Deposit: April 25, 2003

Attorney Docket No. 25619-501 (Formerly 01/21885)

APR 3 0 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

MARPLICANTS:

Schoenfeld et al.

SERIAL NUMBER:

09/806,400

EXAMINER:

R. Schwadron

FILING DATE:

March 30, 2001

ART UNIT:

1644

For:

COMPOSITIONS FOR THE PREVENTION AND/OR TREATMENT OF ATHEROSCLEROSIS

April 25, 2003

Boston, Massachusetts

Assistant Commissioner for Patents Washington, D.C. 20231

RESPONSE TO THE RESTRICTION REQUIREMENT AND PRELIMINARY AMENDMENT

This is in response to the Restriction Requirement dated March 25, 2003 (Paper No. 19). A response is due on or before April 25, 2003. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311 (Reference No. 25619-501).

Prior to examination, please amend the application as set forth below and consider the following remarks:

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 4 of this paper.

JV.

5/1/03